



The Institute

basil hetzel institute for translational health research

MONTHLY BULLETIN FOR TQEH RESEARCH COMMUNITY

WINNING NEWS

www.basilhetzelinstitute.com.au

Follow us 

NHMRC and other Grant Successes!

Congratulations to **Associate Professors Sarah Vreugde, Alkis Psaltis and Dr Nicky Thomas** (ENT Surgery), **Associate Professor Wendy Ingman** (Breast Biology and Cancer Unit), **Professor Catherine Hill** (Rheumatology Research Group) and **Dr Sam Costello** (Inflammatory Bowel Disease Research Group) who are all part of collaborative teams that have received NHMRC Project Grants in the round announced on 12th December.



Director of Research at the Basil Hetzel Institute, TQEH, Professor Guy Maddern (top centre), celebrates the end of a successful year with fellow BHI, TQEH researchers!

DECEMBER 2018

ISSUE 118

IN THIS ISSUE

- p 3 News
- p 18 Student News
- p 21 Community Engagement
- p 23 General Information
- p 25 Publications
- p 27 THRF News

BHI SEMINARS

**All seminar programs
resume in early 2019**

**BHI Invited External Speaker
Research Seminar**
Wednesday 27 February 2019
1-2pm
Professor John Spertus

UPCOMING EVENTS

BHI End of Year Celebration
Wednesday 19 December 2018
lunch from 12pm
BHI Atrium

BHI HUB

From the BHI Facility Manager Kathryn Hudson

BHI Ground Floor
Phone ext: 27427
kathryn.hudson@sa.gov.au



From the BHI Communications Officer Rebecca Anderson

BHI Ground Floor
Phone ext: 27345
rebecca.anderson@adelaide.edu.au
Work days: 9-3pm Tuesday - Thursday



Congratulations to the recently announced NHMRC project grant winners as published in this edition of the BHI Winning News. As 2018 comes to an end, it is a chance to reflect upon some of the BHI successes of the year, which again highlight that our Institute continues to “punch above its weight” in many respects.

Researchers associated with the BHI were awarded one quarter (3 of the 11) of NHMRC Early Career Fellowships awarded to South Australians: **Dr Cher-Rin Chong**, Cardiology – returns from Oxford in 2019; **Dr Bill Panagopoulos**, Breast Cancer Research Unit; **Dr Katharina Richter**, Surgery.

In addition to the newly announced 2019 NHMRC funding, BHI Researchers were Chief Investigators on new 2018 NHMRC grants: 1 x Partnership grant to **Prof John Beltrame** (CIA) and **Dr Rosanna Tavella** (CIB); 1 x Centre for Research Excellence grant to **Prof Bob Adams** in collaboration with Flinders University researchers; 2 x Project grants to **Prof Betty Sallustio** and **Dr Peter Zalewski**. These were in addition to other grants awarded in 2018, including the \$2.53 million awarded to BHI researchers by The Hospital Research Foundation.

Over 40 high profile international presentations were given by TQEH researchers in 2018.

Many research events were held at the BHI throughout the year which culminated in the TQEH Research Expo and included another successful TQEH Researcher Showcase. Throughout 2018 we also held over 70 scientific seminars at the BHI (staff,

external speaker and postgraduate seminars), and well over 50 community engagement activities by TQEH researchers, including: radio interviews, media articles, secondary school student visits, public talk & tours, Science Alive! and “Day of Immunology” talks.

This was all conducted within an everchanging environment including a changed service profile at TQEH, new leadership positions at both The University of Adelaide (new Vice-Chancellor Prof Peter Rathjen) and within CALHN with Lesley Dwyer starting as CEO. Dr Ian Tindall took up the role of Human Research Ethics Chair, and the TQEH/LMH committee merged with the RAH to form a single committee.

The announcement of a \$270m clinical services building at TQEH (due 2022) provides some opportunities for clinical trials to improve their mode of delivery. Users are currently involved in workshopping design briefs.

Unfortunately, the animal ethics committee arrangements at TQEH were not able to be resolved in 2018, however it is hoped this will occur soon.

No doubt 2019 will bring more successes and occasional challenges, but we look forward to working with you and your collaborators to both celebrate and navigate the solutions!

Thanks to everyone here it is a pleasure to work with you all. Have a Merry Christmas, a Happy New Year and hope you can enjoy a well-deserved break over summer!

NEWS

NHMRC Project Grant Successes

Congratulations to BHI, TQEH researchers Associate Professors Sarah Vreugde and Alkis Psaltis, Dr Nicky Thomas (ENT Surgery), Associate Professor Wendy Ingman (Breast Biology and Cancer Unit), Professor Catherine Hill (Rheumatology Research Group) and Dr Sam Costello (Inflammatory Bowel Disease Research Group) who are all part of collaborative teams that have received NHMRC Project Grants in the funding round announced on 12th December 2018.

NHMRC Project Grant (#1164562)

Maximising the antimicrobial and anti-inflammatory performance of next generation therapeutics for Chronic Rhinosinusitis

\$767,389

2019 - 2021

CIA A/Prof Sarah Vreugde, The University of Adelaide

CIB A/Prof Alkis Psaltis, The University of Adelaide & CALHN


CIC Prof Clive Prestidge, University of South Australia

CID Dr Nicky Thomas, University of South Australia




A/Prof Sarah Vreugde

Chronic Rhinosinusitis (CRS) is a common complex disease characterised by chronic inflammation of the sinonasal mucosa associated with bacterial infection and biofilms, affecting as many as 1.8 million (9.2%) Australians. Medical treatment for CRS includes intranasal corticosteroids (CS) and antibiotics but failure of antibiotics to eradicate mucosal biofilms, increasing antibiotic resistance and the inefficient delivery of CS to the site of inflammation render these treatments ineffective. CS are currently prepared in water-based solutions, however, CS have a low solubility in water and form large insoluble aggregates that penetrate poorly through mucosal biofilms and mucus. Consequently, only a fraction of CS effectively reach their target glucocorticoid receptors within the inflamed nasal and sinus tissue. This inter-disciplinary project between researchers from the University of Adelaide ENT Department and the University of South Australia Pharmacy Department will develop nanoparticles that can effectively solubilize CS and have “built-in” anti-microbial and biofilm dispersal effects. It is thought that those nanoparticles will potentiate the effect of CS with improved anti-inflammatory action at lower CS concentrations. *In vitro* proof-of-concept data using established disease-relevant experimental systems will provide safety and efficacy rationale for experimentation into our large animal model of sinusitis towards rapid translation in the clinic.



A/Prof Alkis Psaltis



Dr Nicky Thomas

NHMRC Project Grant Successes (continued)

NHMRC Project Grant (#1165457)

OPTimising Mothers' Own Milk supply in the neonatal unit – enhancing breast milk supply with Domperidone in mothers of preterm infants (OPTIMOM-D)

\$980,000

2019 - 2021

CIA Dr Luke Grzeskowiak, The University of Adelaide

CIB A/Prof Lisa Amir, La Trobe University, Victoria

CIC A/Prof Lisa Smithers, The University of Adelaide

CID A/Prof Susan Jacobs, The Royal Women's Hospital Melbourne, Victoria

CIE A/Prof Wendy Ingman, The University of Adelaide

CIF A/Prof Rosalie Grivell, Flinders University of South Australia



A/Prof Wendy Ingman

Mothers of preterm infants face many challenges in establishing and maintaining an adequate supply of breast milk during their infant's prolonged hospitalisation, due to physiological immaturity of the breast associated with preterm birth, inability for the preterm infant to breastfeed directly from the breast, or the stress of having an infant admitted to the Neonatal Intensive Care Unit (NICU). This study will investigate the optimal dose of domperidone in stimulating increased volume of breast milk in mothers of preterm infants, and why this galactagogue is ineffective in 30% of women struggling to breastfeed. We have previously shown that lactation insufficiency can be caused by innate inflammatory signalling in the breast and members of the research team at BHI will explore whether inflammatory mediators can be a predictor of domperidone treatment response, or could be used to identify alternative pharmacological treatments. This research will determine optimal treatment regimens for managing low milk supply in mothers of preterm infants and directly inform clinical guidelines, that will provide significant infant, maternal, and societal benefits from improvements in breastfeeding.

NHMRC Project Grant Successes (continued)

NHMRC Project Grant (#1161634)

Targeting unhelpful pain beliefs to promote physical activity in people with knee osteoarthritis: a multi-centre, randomised controlled trial with cost-effectiveness analysis

\$1,196,257

2019 - 2021

CIA Dr Natasha Stanton, University of South Australia
CIB Professor G Lorimer Moseley, University of South Australia
CIC Professor Catherine Hill, The University of Adelaide & CALHN



Professor Catherine Hill

Physical inactivity is a serious problem in people with knee osteoarthritis (OA): they are not active enough to maintain their health and inactivity often makes their OA symptoms worse. In a large clinical trial, we will test a promising new treatment – pain biology education – for its ability to improve physical activity and pain. Our pilot work shows promising results: in 139 people with knee OA this treatment increases activity and reduces pain with improvements continuing for up to 1 year. We will recruit patients in South Australia and Victoria to be part of this study.

NHMRC Project Grant (#1156333)

Characterisation of mobile antimicrobial resistance in the human gastrointestinal microbiota

\$878,108

2019 - 2021

CIA Dr Samuel Forster, Hudson Institute of Medical Research, Monash University, Victoria & Wellcome Trust Sanger Institute, Cambridge, UK
CIB Dr Trevor Lawley, Wellcome Trust Sanger Institute, Cambridge, UK
CIC Dr Sam Costello, The University of Adelaide & CALHN



Dr Sam Costello

Antimicrobial resistance (AMR) is emerging at an alarming level, rendering some bacterial infections untreatable and increasing dependence on last line antibiotics. This project will seek to characterise antimicrobial resistance within the naturally occurring gut bacteria to inform clinical antibiotic selection and minimise the emergence and spread of antibiotic resistance within the hospital and community setting.

US Food and Drug Administration (FDA) Grants awarded to Therapeutics Research Centre leader Professor Michael Roberts

The University of South Australia (UniSA) and the University of Queensland (UQ) are leading two grants awarded via the US Federal Drug Administration (FDA) Generic Drug User Fee Amendments (GDUFA) in a round which saw 23 international collaborative research contracts and grants awarded, with most grants being awarded to US institutions. **Professor Michael Roberts**, an Australian National Health & Medical Research Council Senior Principal Research Fellow, will lead both grants involving his research teams working across the University of South Australia (UniSA), located in the Basil Hetzel Institute for Translational Health Research (BHI), and the University of Queensland Diamantina Institute (UQ-DI), based at the Translational Research Institute (TRI). He will be supported by co-principal investigator, Dr Yousuf Mohammed (UQ-DI), with one grant managed at UniSA by **Dr Lorraine Mackenzie** and undertaken by his team including, **Dr Azadeh Alinaghi, Dr Amy Holmes, Dr Tom Robertson and Associate Professor John van de Hoek**, and collaborators in the USA, UK, Germany and Brazil and the other managed at UQ by Dr Jeff Grice at TRI the team there.



Professor Michael Roberts

Bioequivalence of Topical Products: Elucidating the Thermodynamic and Functional Characteristics of Compositionally Different Topical Formulations

University of South Australia (1U01FD006496)

US \$1.25M

September 2018 - September 2023

The UniSA managed grant that involves UQ, will focus on gaining a better understand how variations in the composition and the nature of topical drug formulations can impact on their absorption and performance in human skin. The work will aid innovator and generic companies in the development of new topical dermatological products and assist the FDA in its regulatory evaluation of which topical products may have a similar performance in human skin to reference products.

Details of all the GDUFA 2018 grants can be found [here](#).

Formulation Drug Product Quality Attributes in Dermal Physiologically-Based Pharmacokinetic Models for Topical Dermatological Drug Products and Transdermal Delivery Systems

University of Queensland (1U01FD006522)

US \$0.5M

September 2018 - September 2020

The UQ managed grant, in collaboration with UniSA, will seek to understand how interactions between products of different composition and human skin impacts on the local and systemic effects of the pharmaceutical active after topical application. A key goal is to use this understanding to accurately predict topical product performance in patients and, in so doing, increase the certainty and reduce the costs of any clinical trials that may be undertaken to validate a new product's performance in those patients. This work will also support the company Certara in their further development of their global software that now supports innovator and generic product manufacturers in their design and testing of new products and can assist the FDA in its regulatory evaluation of those products.

Certara was also awarded a further grant from the GDUFA scheme that will involve a collaboration with Prof Roberts and his team in Australia addressing the impact of skin disease on topical absorption.

Channel 7 Children's Research Foundation/ THRF Project Grant

**A pre-clinical evaluation of an innovative
DNA-based vaccination regimen to protect
women of childbearing age against Zika
virus during sexual transmission**

\$240,000

2019-2020



L-R: Prof Eric Gowans, Dr Ashish Shrestha and Dr Dan Wijesundara

CIA Dr Danushka Wijesundara, Virology Group, The University of Adelaide

CIB Professor Eric Gowans, Virology Group, The University of Adelaide

CIC Professor Sarah Robertson, Robinson Research Institute, The University of Adelaide

CID Dr Branka Grubor-Bauk, Virology Group, The University of Adelaide

CIE Dr Ashish Shrestha, Virology Group, The University of Adelaide

Since the recent Brazilian outbreak, Zika virus is recognized to cause severe damage to developing foetuses in pregnant women leading to children born with partially collapsed skulls, decreased brain tissue, damaged eyes and restricted body movements. It is now recognized that sexual transmission is a significant driver of the Zika virus epidemic, but there is no vaccine or medicine to eliminate the virus in women shortly after sexual transmission. Thus, this project will develop a cost-effective vaccine which can evoke a frontline defence capable of eliminating Zika virus shortly after its exposure in the vagina.



The Garnett Passe and Rodney Williams Memorial Foundation



**A novel treatment for *S.aureus* recalcitrant
chronic rhinosinusitis**

\$375,000

2019-2021



CIA Prof PJ Wormald, ENT Surgery, The University of Adelaide & CALHN

CIB A/Prof Sarah Vreugde, ENT Surgery, The University of Adelaide

Adelaide Enterprise Commercial Accelerator Scheme (CAS) with matched THRF funding support

A novel vaccine against Zika virus

\$200,000

2019



the hospital
research foundation

CIA Dr Branka Grubor-Bauk, Virology Group, The University of Adelaide
CIB Dr Danushka K Wijesundara, Virology Group, The University of Adelaide
CIC Professor Eric J Gowans, Virology Group, The University of Adelaide

The Virology Group will perform a series of preclinical studies in mice and pigs to determine the optimum dose of our vaccine against the Zika virus. The work will be performed entirely in Adelaide and will determine the dose and frequency of multiple doses should these prove necessary. The studies will conclude with vaccination studies in a large animal model, the pig, because the immune system of pigs is very similar to that of humans, and adult pigs have a similar weight to adult humans. Consequently, we expect that the pig studies will identify a vaccine regimen that will be applicable to the human clinical trials proposed in the next phase of the program. *Eric Gowans*



Above L-R: Dr Michael Muthig (Senior Commercial Manager, Adelaide Enterprise) and Paul Flynn (CEO, THRF) presenting Dr Branka Grubor-Bauk and Prof Eric Gowans with their CAS/THRF Award. Below: The gathered crowd!



Results from TARGET study presented at ESICM, published in the NEJM and reported in The Lancet

Professor Sandra Peake, Director of Intensive Care Medicine at TQEH, and Professor Marianne Chapman, RAH Intensive Care Medicine) presented results from the TARGET study (The Augmented versus Routine approach to Giving Energy Trial) at the President's Ground-breaking Research session at the European Society Intensive Care Medicine Congress in Paris. This October meeting was attended by approximately 6000 delegates.

The New England Journal of Medicine (NEJM) coordinated the simultaneous online publication of their paper "[Energy-Dense versus Routine Enteral Nutrition in the Critically Ill](#)" with the presentation of the results at the Congress.

Following this meeting, the TARGET study was also featured in an article published in The Lancet Respiratory Medicine "[Round-up of the European Society of Intensive Care Medicine Congress 2018](#)".

Summary of TARGET study:

Nutrition is an essential standard of care for all critically ill patients who remain in the ICU for more than a few days. Usual practice typically delivers only 50-70% of international guideline-recommended calories.

The TARGET trial was a 4000-patient, multi-centre, double-blind, randomised, phase III trial evaluating whether increasing calorie delivery using energy-dense (1.5 kcal/ml) versus routine (1.0 kcal/ml) enteral nutrition formulation improves 90-day survival in mechanically ventilated adults.

TARGET was funded by a project grant from the NHMRC and the Health Research Council of New Zealand and endorsed by the ANZICS Clinical Trials Group. The trial was coordinated by the ANZIC Research Centre (Monash University) and supported by the Centre of Research Excellence for the Translation of Nutritional Science into Good Health (Adelaide University).

The trial was led by Professor Sandra Peake from Department of Intensive Care Medicine, The Queen Elizabeth Hospital and Professor Marianne Chapman from Critical Care, RAH. ICU research coordinators Patricia Williams (TQEH) and Stephanie O'Connor (RAH) were members of the study management committee and working party. TQEH and RAH ICU's were



L-R: Professors Sandra Peake (TQEH) and Marianne Chapman (RAH) at the European Congress.

lead sites with a total of 46 intensive care units throughout Australia and New Zealand participating in the study.

4000 patients were recruited over 17 months with the study nutrition delivered for a median of 6 days. Patients in the energy-dense group received 47.6% more calories than patients in the routine enteral nutrition group.

There was no difference in 90-day mortality (27% versus 26%) or in any secondary outcomes including ICU and hospital-free days, receipt of organ support and infectious complications. Patients in the energy-dense group experienced increased upper gastrointestinal intolerance and increased insulin administration

TARGET is the largest blinded randomised trial of enteral nutrition to be conducted in the critically ill. It is also the first trial to deliver full-recommended calories. Professor Sandra Peake says "TARGET provides the best evidence to date regarding optimal calories delivery in the critically ill. Our results do not support current guideline recommendations. However, we await the ongoing analyses of long-term (6 months) functional outcomes, the results of which will be available in early 2019, before making any definitive conclusions".

The CRE in Frailty and Healthy Ageing attended the 51st Australian Association of Gerontology Conference



L-R: Drs Danielle Taylor and Agathe Daria Jadczyk, at the Australian Association of Gerontology conference

On November 21-23 CRE Researchers and students took part in the 51st Australian Association of Gerontology conference in Melbourne, Australia.

The special theme of this years conference was 'Advancing Not Retiring: Active Players, A Fair Future'. The plenary speaker for the event was Professor Sir Michael Marmot, Director of the International Institute for Society and Health, MRC Research Professor of Epidemiology and Public Health, University College, London. Prof Marmot gave a fascinating presentation on "Social determinants of health, the life course, and healthy ageing".

On Wednesday CRE Frailty & Healthy Ageing Research Fellow and PhD candidate Rachel Ambagtsheer presented "An electronic Frailty Index for Australian general practice" during the Innovation and Technology oral presentations. Dr Helen Barrie, CRE Frailty & Healthy Ageing demographer and gerontologist, gave a presentation on 'Using citizen science to explore neighbourhood influences on ageing well' during the Ageing Well program on Thursday.

Then on Friday, CRE Frailty researcher Dr Danielle Taylor presented her work on "Developing a spatial socio-environment healthy ageing index" whilst Dr Agathe Daria Jadczyk discussed "Interns' perceived competence in counselling older adults about exercise: findings from a 3-year South Australian study" during the Falls and Exercise program.

Despite the cold and rainy weather the three day event was a great success bringing experts together from around Australia and the world to share research and learn from a network of researchers, advocates, clinicians and students.

2018 ASCEPT meeting held in Adelaide



Attending the ASCEPT Conference Dinner were (above, L-R) Shane Spencer, Betty Sallustio and Paul Flynn (THRF) together with (right, L-R) John Licari, Lorraine Webster (Bellberry Ltd, Victoria) and Rong Hu.



During the last week of November, Adelaide was host to the annual scientific meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). This meeting, generously sponsored by The Hospital Research Foundation, brought together over 300 delegates from around Australia, New Zealand, the US, Europe and Asia to address the theme Innovation in therapeutics: Fundamental research to clinical impact.

There were many outstanding national and international speakers including: Professor Andrew Somogyi (University of Adelaide) who explained how ketamine - normally used as an anaesthetic – has the potential to be used in the treatment of severe depression; Professor Daria Mochly-Rosen (Stanford University, USA) who gave an inspiring opening plenary lecture on the challenges of translating new discoveries in science and technology into novel treatments and therapeutics; Professor Steven Charlton (University of Nottingham, UK) who demonstrated how new technology that allows measurement of drug concentrations within cells is revolutionising our understanding of the effectiveness of

drugs; Dr John Thompson (National Poisons Information Service, UK) who spoke about the increasing number of new recreational drugs appearing on the market over the last few years, the challenges of detecting these compounds and treating their adverse effects; and Professor Andrew McLachlan (University of Sydney) who discussed pain as a multidimensional health condition that requires a multidisciplinary approach to find effective therapies.

BHI staff were well represented at the meeting, including: Dr Betty Sallustio who was on the local organising committee and a speaker at the Pharmacogenomics workshop, as well as Dr John Licari, Shane Spencer and Rong Hu from Clinical Pharmacology; Prof John Horowitz and Irene Stafford from Cardiology; and Muhammad Suleman Khan from the Therapeutics Research Group. Clinical Pharmacology were also Paul Flynn's guests at the Conference Dinner where we were able to put our pharmacological knowledge to the test and guess the mystery wine. Unfortunately we will need to do more research Paul!!

Betty Sallustio

Recent promotions at The University of Adelaide



Announcements of Academic Staff Promotions at The University of Adelaide were made at the Faculty of Health and Medical Sciences Forum last week. **Professor Betty Sallusio**, Clinical Pharmacology Research Group (*photo left*), was promoted to Level E titleholder Professor and **Associate Professor Anupam Datta Gupta**, Adelaide G-TRAC (*photo right*), was promoted to a Level D titleholder Associate Professor.



PhDs conferred by The University of Adelaide



Dr Jae Murphy, ENT Surgery, (*photo left*) has received his PhD and also received a Dean's Commendation for Doctoral Thesis Excellence for his thesis "The mucosal barrier in Chronic Rhinosinusitis". Jae completed his PhD under the supervision of Professor PJ Wormald and Associate Professor Sarah Vreugde.

Dr Chuks Ajaero, Cardiovascular Pathophysiology and Therapeutics Group, (*photo right*) has also qualified for his PhD which he completed under the supervision of Professor John Horowitz. His thesis title was "Interactions between Cardiac Resynchronisation Therapy and Amelioration of Peripheral Vascular Dysfunction: Impact upon Outcomes".



ASMR Champion Ma Playoust Award



Dr Lisa Cherian, PhD student in ENT Surgery, won the Champion Ma Playoust Award at the ASMR national conference for the best presentation by an early career researcher. Lisa presented her results on "the effect of the excipients in commercial nasal steroids on bacterial growth" (excipients being inactive substances that serve as the vehicle or medium for a drug or other active substance).



MIT Technology Review Innovators

Dr Katharina Richter, ENT Surgery (*photo left*), has been named as one of the top 10 innovators in the MIT Technology Review Innovators Under 35 competition for the Australia, Hong Kong, New Zealand, Southeast Asia and Taiwan region. As part of this nomination, Kati will present her research at the next EmTech Asia conference in January 2019.



Best Clinical Prize at ARA meeting


Charlotte Proudman (*photo right*), who undertook a 4th year research elective as a medical student with the Rheumatology Research Group at the BHI, TQEH, received the "Best Clinical Prize" at the Australian Rheumatology Association Annual Scientific Meeting held in November.

THRF Travel Award Report: Dr Makutiro Masavuli

Dr Makutiro Masavuli, Virology Group, Discipline of Surgery.
Supervisor: Professor Eric Gowans

Attended the 25th International Symposium on Hepatitis C Virus and Related Viruses (HCV2018)

Dublin, Ireland
October 2018



I presented a poster and attended as many sessions as I could during the conference. Some of the presentations were interesting and provided new insight into vaccine development against HCV and related viruses. In particular, there was a presentation on the development a HCV envelope glycoprotein vaccine with a T cell component designed to elicit cross-neutralizing antibodies and broadly cross-reactive T cell responses. Vaccination with these glycoprotein components in humans and animal models elicited neutralizing antibodies that can recognize all HCV major genotypes.

Another presentation focused on a vaccine against Zika virus designed to elicit highly specific neutralizing antibodies, and hopefully overcoming the risk of Antibody-Dependent Enhancement (ADE) of other Flavivirus infection such as the Dengue virus. This vaccine incorporated a modified version of the Zika virus envelope protein that prevented the trimerization of the envelope protein thus avoiding the exposure of epitopes recognized by cross-reactive poorly neutralizing antibodies and forcing the viral protein to reveal Envelope Dimer Epitopes (EDE) instead. The researchers reported that this vaccine is a promising element for an effective ZIKV vaccine. In addition to the above, I was inspired by the various keynote speakers including Prof. Ellie Barnes, Prof. Ralf Bartenschlager, Dr. Gisa Gerold, Dr. Gottfried Hirnschall, Dr. Stacy Horner, Prof. Diarmuid Houlihan, Prof. Will Irving, Dr. Seungtaek Kim, and Dr. Jean-Michel Pawlotsky.

How did the conference impact your research?

I'm currently writing a manuscript from my PhD research and attending the conference allowed me to compare my vaccine strategy against others and ensure that my final manuscript reflects the most recent relevant HCV vaccine strategies in the industry.

What does this travel grant mean for your future research?

Thanks to the grant, I was able to have discussions in person with some of the senior members of the HCV community regarding my research. This has provided me with new aspects to consider in my own research and ways in which my vaccine strategy could still be improved.

In a few sentences, could you please sum up your experience?

I attended last year's conference in the USA thanks to the support of the THRF and this year it was exciting to receive an update on some of the research on HCV and related viruses as well as vaccine development being conducted around the world. Additionally, I received considerable feedback on my research from senior members of the HCV research community and made new connections that will hopefully result in fruitful collaboration in the future. I was very impressed by the conference, the high level of science and the many stimulating talks. I am sure I will be able to translate this experience and the many inspirations into my own research here at TQEH.

THRF Travel Award Report: Dr Tharshy Pasupathy

Dr Sivabaskari Pasupathy, Translational Vascular Function Research Collaborative, Cardiology.
Supervisor: Professor John Beltrame

Attended the American Heart Association scientific sessions 2018

Chicago, USA
November 2018

L-R: Professors John Beltrame and John Spertus (University of Missouri, USA) with Drs Tharshy Pasupathy and Rosanna Tavella. John Spertus is a long-term collaborator with John Beltrame and his group, and was awarded as the Most Distinguished Scientist for 2018 by the AHA.



I was invited as an early career blogger by the American Heart Association and it was a very rewarding experience. I had the privilege to attend the embargoed sessions and late breaking trials at the conference and had the opportunity to both share my opinion on the American Heart Association website and the twitter feed. I was able to present my first blog on MINOCA on the AHA website. <https://earlycareervoice.professional.heart.org/minoca-the-new-unique-type-of-myocardial-infarction/>

As an Australian Early Career Blogger I will be able to continue sharing my research in the blog form of the American Heart Association website for upcoming months.

I also presented our MINOCA research from Adelaide as a poster at the conference and I had a significant number of visitors at my poster with many intriguing discussions and feedbacks. I have had several discussions with MINOCA research experts from all over the world and formed collaborations and new directions to enhance our current research.

This Travel Award gave me the unique opportunity to establish connections that will further help my career and research.

BHI Invited External Speaker Research Seminar

Wednesday 27 February 2019

1 - 2pm

PROFESSOR JOHN SPERTUS

BHI Ground Floor Seminar Rooms

37a Woodville Road, Woodville South

THRF Travel Award Report: Zelalem Mekonnen

Zelalem Mekonnen, PhD Student, Virology Group, Discipline of Surgery.
Supervisor: Professor Eric Gowans

Attended the 25th International symposium on Hepatitis C virus and related viruses (HCV2018).

Dublin, Ireland
8-11 October 2018

Please provide a description of your time there.

Apart from attending this conference my abstract was selected for poster presentation. I presented my work to the attendees during all the poster sessions.

Could you please explain any outcomes you achieved from the event?

I had interactions with senior scientists who are working on HCV vaccine development. As a result of this Prof. Ellie Barnes, a senior scientist in HCV vaccine development, was interested in my work and mentioned to me that she is happy to examine my thesis. I was also able to meet one of my previous colleagues who is currently working on HCV in Germany. We had a good time and discussed future job opportunities in the lab he belongs to. We are still communicating to make progress.

How did the conference impact your research?

The conference had eight themes in research on HCV and other related viruses. My research was in theme 4 "Vaccine and anti-viral agents". From the research presented in this theme I learned that my research has a potential to grow as far as a vaccine to induce cell mediated immune response against HCV is concerned.

What does this travel grant mean for your future research?

I gained a lot from this symposium. As a scientist working on vaccine development, I learned the shared problems in the area of vaccine development. In addition, the development of HCV research presented by Prof. Charlie Rice showed where the future of HCV research will be. To this end it was encouraging; vaccine development is the area that has lots of open space.

In a few sentences, could you please sum up your experience?

Over all the conference was educational and my stay in Dublin was great. Meeting a colleague after five years of no communication was a big surprise I got from the conference. Who knows, I might end up working with him again. All this was possible due to the support of THRF, so many thanks to the donors.

This was "Science in the City of Guinness"



Welcome to new staff and PhD Students



Dr Naomi Cook

Postdoctoral Researcher, Inflammatory Bowel Disease Research Group, Level 1 BHI

Naomi's research background is mainly in cell and molecular biology and biochemistry. She completed her PhD in neuropathology at The University of Adelaide (2010), investigating the role of neuropeptides and magnesium transporters in neurological diseases. She subsequently worked as a postdoctoral research officer (2010-2014) at the Heart Research Institute in Sydney and also at QIMR in Brisbane, prior to taking up a position in functional genomics research into metabolic diseases at Uppsala University in Sweden (2015-2018). Naomi recently joined the Inflammatory Bowel Disease Research Group to assist with research projects investigating the role of the microbiome in inflammatory bowel disease and exploring diet and faecal microbial transplantation as potential treatment strategies.



Dr Joanna Tieu

PhD Student, Rheumatology Research Group, Level 2 BHI

Supervisors: Cleland L, Hill C, Proudman S, Peh CA, Jayne D

Thesis Title: Optimising therapy in ANCA-associated Vasculitis

Scholarship: NHMRC Postgraduate Scholarship and the Ken Muirden Overseas Training Fellowship from Arthritis Australia

joanna.tieu@adelaide.edu.au

Joanna is a Rheumatologist, continuing her PhD in the Rheumatology research group at BHI, focused on treatment strategies in ANCA associated vasculitis (ANCA = anti-neutrophil cytoplasmic antibody). This is a group of diseases characterised by the destruction and inflammation of small blood vessels. She has recently returned from study leave in the United Kingdom, with Professor David Jayne, University of Cambridge.



Sholeh Feizi

PhD Student, ENT Surgery, Level 1 BHI

Supervisors: Associate Professor Sarah Vreugde and Professor PJ Wormald

Thesis Title: Green synthesis of silver nanoparticles and their biomedical applications

Scholarship: Adelaide ENT Research Institute Scholarship with corresponding Full Fee Scholarship from The University of Adelaide

sholeh.feizi@adelaide.edu.au

Sholeh received her Master of Science in Biochemistry from the University of Alzahra in Iran in 2015. During her MSc she worked on green synthesis of silver nanoparticles and their biomedical applications. In 2012 Sholeh obtained her BSc Animal Biology from Shahid Beheshti University in Iran. She has worked as a research assistant for two years in the field of nanoparticle research and has published three papers in peer-reviewed journals and participated in four national and international conferences. Her research interest is in green synthesis of nanoparticles and their biomedical applications.

...and Welcome to the BHI 2018-2019 Summer Vacation Students



L-R: Amanthi Mendis, April De Sliva, Emily Hammond, Tim Lee, Bola Jeong, Mengqi (Adele) Zhou, Yianni (John) Glynatsis and Harrison Bolt.

There are 13 summer vacation students spending their summer at the BHI, TQEH. 10 of these students are being supported by THRF/TQEH Department scholarships. Please make them feel welcome!

Student Name	TQEH Department/Research Group
Harrison Bolt	ENT Surgery
April De Silva	ENT Surgery
John Glynatsis	ENT Surgery
Emily Hammond	ENT Surgery
Bola Jeong	ENT Surgery
Tim Lee	ENT Surgery
Amanthi Mendis	ENT Surgery
Ashley Twigger	ENT Surgery
Neha Kasture	Medicine / The Health Observatory
Ben Ngoi	Medicine / TVFRC (Beltrame)
Adele Zhou	Aged and Extended Care Services
Katarina Foley	Surgery / Surgical Science Research Group
Janine Vu	Surgery / Surgical Science Research Group

BHI STUDENT NEWS

BHI STUDENT REPS 2018-2019



Clementine Labrosciano (Level 2)
clementine.labrosciano@adelaide.edu.au



Sarah Bernhardt (Level 1)
sarah.bernhardt@adelaide.edu.au



Joe Wrin (Level 1)
joe.wrin@adelaide.edu.au



On Thursday 29th of November, the BHI had it's quiz afternoon hosted by the student reps. It was a great opportunity for everyone to test their knowledge and enjoy some pizza and drinks kindly supplied by the Hospital Research Foundation. With controversial questions such as "who is the Australian prime minister (today)?" and the difficulty of identifying different flags - we hope everyone learnt something new. The student reps would like to thank all that attended the event and congratulate our winners "The Big Hairy Intellectuals (BHI)" pictured below: L-R: **Adrian Abdo, Jessica Reid, Prue Cowled, Leonie Baker and Lisa Leopardi.**



Coffee, chat & mindfulness

"Coffee and Chat" is a new student rep initiative aimed at providing all staff, students and supervisors with the opportunity to socialise and network in a casual environment. Students are able to discuss issues they are having with their studies with other students and staff.

2pm every Wednesday
BHI Ground floor seminar rooms

At 3pm we will be running a short (10-15 minutes) guided mindfulness session that has been run at BHI by previous student reps.

BHI STUDENT NEWS CONTINUED

This year the student reps are running a Christmas “Decorate your Workspace” competition to bring some Xmas cheer to the BHI! The best decorated workspace at the BHI will win a prize at our end of year celebrations on Wednesday 19th December. Judging will take place on the Monday - Wednesday of that week. Here are some photos from around the BHI, and it looks like Level 1 has a bit of work to do over the weekend!



BHI STUDENT NEWS

CONTINUED

The BHI End of Year Celebration is the last event being organised by the BHI Student Reps for 2018. Don't forget to thank Sarah, Clementine and Joe for all the effort they have put into the various activities at the BHI since they started as reps in July this year!



COMMUNITY ENGAGEMENT



the hospital
research foundation

Community Group Presentations

THRF are always looking for BHI researchers to present at community events. It is a wonderful opportunity for you to practice your public speaking skills, and present your work to a lay audience! If you are interested or would like some more information, please contact Tamara at THRF on 8244 1100 or tpietraszuk@hospitalresearch.com.au

THRF Talk and Tour visit: 8 November 2018



Women from The Sharon Forrester-Jones Racing Group spent a morning at the BHI listening to A/Prof Wendy Ingman talk about Breast Density before being taken on a tour of the labs and speaking with various researchers including Dr Kevin Fenix (photo, bottom left). The group donated \$500 towards The Hospital Research Foundation.

The Advertiser: 22 November 2018

An article in The Advertiser reported Kati's recent nomination as one of the top 10 innovators in the MIT Technology Review Innovators Under 35 competition (see earlier story in this edition of Winning News).

ADVERTISER.COM.AU THURSDAY NOVEMBER 22 2018



The Medical Republic: 14 November 2018

A/Prof Wendy Ingman, Breast Biology and Cancer Unit, had an article on "[Breast Density: What's all the fuss about?](#)" published in The Medical Republic, who describe themselves as "a group of doctors, journos and 'old world' publishers" who aim to provide up to date info for doctors and patients alike.



LIFESAVING: Katharina Richter is investigating treatments to halt the global rise of antibiotic-resistant bacteria. Picture MATT TURNER

Bug-busting work leads world

ELISA BLACK
RESEARCH REPORTER

NOVEL superbug treatments including a "toxic chocolate" for bacteria have led to a University of Adelaide scientist netting a top 10 innovator award.

Dr Katharina Richter was last night named as one of the top 10 innovators in the MIT Technology Review Innovators Under-35 competition for the Australia, Hong Kong, New Zealand, Southeast Asia and Taiwan region.

Previous winners include Google founder Larry Page and Facebook's Mark Zuckerberg.

Dr Richter received the award for her work fighting antibiotic-resistant bacteria. Superbugs, such as Golden Staph, cause 700,000 deaths globally every year as existing antibiotics cannot effectively kill them.

Her first treatment is a post-surgical nasal rinse that destroys residual bacteria which can lead to further surgery.

The second is a non-toxic wound-healing gel, also applied after surgery, which first starves bacteria and then feeds them the bacterial equivalent of toxic chocolate.

The two treatments have

progressed to clinical applications, with trials conducted at the Queen Elizabeth Hospital. Dr Richter said her treatments had the potential to improve the lives of the three million Australians who suffer from chronic sinus infections.

"The treatments could effectively kill the superbugs, reducing the need to take antibiotics and preventing surgery which, up to now, has been the only method of treating this debilitating condition," she said.

Results from ongoing clinical trials will help refine the treatments for applications in other infectious diseases.

Radio and TV interviews



Dr Amy Holmes, postdoctoral researcher in the Therapeutics Research Centre gave a live radio interview to ABC Sunshine coast on Monday 26 November, pre-recorded an interview for Radio National News and appeared on the [Channel 7 news](#) on Wednesday 28 November talking about their recent study on sunscreen safety.

This study was a collaborative project with the University of Queensland, where TRC research leader, Professor Michael Roberts, has another team of researchers. Amy and research assistant **Dr Isha Haridass** were the two BHI based TRC people who worked on this project.

Amy writes “There is a lot of controversy when it comes to applying engineered nanoparticles to our skin and concern was raised from cell and animal based studies that repeated application of zinc oxide based nano particles used in sunscreens may help them to penetrate our skin and become absorbed to cause skin damage. We applied zinc oxide nanoparticles based sunscreens to volunteers and using a state-of-the-art microscope we imaged the signal from these nanoparticles and found that even after repeated application no nanoparticles penetrated the skin barrier. Further, no cellular toxicity was observed in the skin where the nanoparticles based sunscreen was applied. We hope these findings alleviate any consumer concerns regarding sunscreen use.

A University of South Australia press release was issued due to a recent publication in the [Journal of Investigative Dermatology](#). The story has since featured websites including [The Lead, South Australia](#) and [Kids on the Coast](#).

BHI receives award from School

Portside Christian College have awarded the BHI the “John Ridley Service Award” for service to their school. For over 5 years the BHI has hosted a student from the college for a week of work experience. The certificate and glass award have been placed in the BHI reception area.

If you know of students entering years 10-12 in 2019 who are interested in undertaking work experience at the BHI, please encourage them to keep an eye on the website. Applications will open in January 2019.

<http://www.basilhetzelinstitute.com.au/students/secondary-student-work-experience/>



GENERAL INFORMATION

STATISTICIAN AT THE BHI

Dr Stuart Howell works at the BHI on Tuesdays. He is available and can be consulted by TQEH/ The University of Adelaide Faculty of Health & Medical Sciences staff and research higher degree students. Support is limited to 15 hours on a per project basis.



Tuesdays
BHI Level 1
Room 1E.07
Phone: 8222 6679
stuart.howell@adelaide.edu.au

Dr Stuart Howell
Senior Statistician
Data, Design and Statistics Services
Adelaide Health Technology Assessment (AHTA)
School of Public Health
The University of Adelaide

Changing of the Stats Guard!

From 2019 **Suzanne Edwards** will be the resident statistician at the BHI as Stuart plans to work part-time on some existing stats projects and spend more time as a photographer. Thanks for all your assistance over recent years Stuart, and all the best for whatever lies ahead.

Hello! I am Suzanne Edwards, a new statistician starting at TQEH in January 2019. I am looking forward to working Tuesdays next year in a statistical consulting role with Basil Hetzel Institute, TQEH staff performing research as well as postgraduate students. My background is as a Registered Nurse, Metallurgical Laboratory Technician and, for the past 11 years as a Statistician at The University of Adelaide. Since 2012 I have been a statistical consultant with [AHTA](#) (Adelaide Health Technology Assessment, School of Public Health, The University of Adelaide), formerly called DMAC. The best way to contact me next year is by email so we can set up a meeting time. I wish my colleague, Dr Stuart Howell, all the best in his future endeavours.

suzanne.edwards@adelaide.edu.au



Suzanne Edwards

TQEH Librarians

anna.holasek@sa.gov.au or rachel.davey@sa.gov.au

A librarian from the SA Health Library Service, The Queen Elizabeth Hospital Campus, is available to assist with constructing suitable literature and database searches for your research requirements and to help you obtain relevant material.

All BHI staff, students and researchers are welcome to visit TQEH Library on level 5B of the main building at any time Monday to Friday between 9am-4.45pm. Alternatively, visit the Library's website (<https://salus.sa.gov.au>) to view our services and resources. To access any of the electronic resources you will need to register for a SALUS username and password with the Library.



The Institute

basil hetzel institute for translational health research

TQEH Research Secretariat Contact Details
Ground Floor, (DX465101)
Basil Hetzel Institute for Translational Health Research
The Queen Elizabeth Hospital
28 Woodville Rd, WOODVILLE SOUTH 5011
Phone: 08 8222 7836 Fax: 08 8222 7872
Email: gwenda.graves@sa.gov.au

GENERAL INFORMATION CONTINUED

Pre-review service for clinical research grants

All research studies, including grant funded research, require appropriate ethics and governance approvals before they can commence. Unlike the NHMRC, many funding bodies do not utilise a peer-review system as part of their grant funding rounds. This can lead to delays in researchers obtaining the post-award approvals that are required before they can start their projects. **The CALHN Research Office is offering pre-application scientific review of clinical human research projects by the CALHN HREC Chair, Mr Ian Tindall, with a view to facilitating efficient post-award approval processes.**

For further information and submission please contact the CALHN Research Office on Health.CALHNResearchEthics@sa.gov.au or call 7117 2230

CALHN Human Research Ethics Committee Submission and Meeting Dates for Applications January & February 2019

Submission to site (sponsored studies)	Submission to HREC	CALHN HREC Meeting	Meeting Group
Friday 04 January	Monday 07 January	Thursday 31 January	A
Friday 18 January	Monday 21 January	Thursday 14 February	B
Friday 01 February	Monday 04 February	Thursday 28 February	A
Friday 15 February	Monday 18 February	Thursday 14 March	B

In 2019 there will be one submission date (and one meeting) each fortnight with the committee split into two meeting groups. Researchers can submit to either meeting group – a full NHMRC prescribed quorum will be present at all meetings. Above are the meeting dates and final dates for submissions of applications for Scientific and Ethical approval.

Any study which includes drug therapy is considered by the Investigational Drug Subcommittee (IDSC) the week prior to the CALHN HREC. Drug studies will be passed on to the CALHN HREC meeting. ALL HREC meetings will continue to be held on Thursdays at Roma Mitchell House, Level 3, 136 North Terrace, Adelaide, and NOT at the BHI, TQEH.

For more information please contact:

Investigational Drugs Subcommittee (IDSC) Mr Peter Siobodian or Dr Ada Lam Executive Officer, Specialist Pharmacist Phone: (08) 7074 1430 or (08) 7074 1150 peter.siobodian@sa.gov.au ada.lam@sa.gov.au	CALHN Human Research Ethics Committee (HREC) Ms Lisa Barrie CALHN HREC Level 3, Roma Mitchell House Phone: (08) 7117 2229 or (08) 8222 6841 Health.CALHNResearchEthics@sa.gov.au
---	--

CALHN Animal Ethics Committee

Further information: John Finnie, SA Pathology/CALHN AEC Committee SAPathologyAEC@sa.gov.au

PUBLICATIONS

If you wish to have a recent publication included, please send details to the BHI Communications Officer
rebecca.anderson@adelaide.edu.au

De Sousa S, Jesudason D. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman. *Clinical Endocrinology*. (no pagination), 2018. DOI: 10.1111/cen.13867.

Dudhwala Z, Drew P, Howarth G, Moore D, Cummins A. Active beta-catenin signaling in the small intestine of humans during infancy. *Digestive Diseases & Sciences*. 2018 Oct. DOI:org/10.1007/s10620-018-5286-y.

Ridley E, Peake S, Jarvis M, Deane A, Lange K, Davies A, Chapman M, Heyland D. Nutrition therapy in Australia and New Zealand Intensive Care Units: An international comparison study. *JPEN: Journal of Parenteral & Enteral Nutrition*. 42(8):1349-1357, 2018 Nov.

Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Comorbidity in psoriatic arthritis and rheumatoid arthritis. *Internal Medicine Journal*. 48(11):1360-1368, 2018 Nov.

Thompson M, Theou O, Adams R, Tucker G, Visvanathan R. Frailty state transitions and associated factors in South Australian older adults. *Geriatrics & Gerontology International*. 18(11):1549-1555, 2018 Nov.

Vieira C, Grice J, Roberts M, Haridass I, Duque M, Lopes P, Leite-Silva V, Martins T. ZnO:sba-15 nanocomposites for potential use in sunscreen: preparation, properties, human skin penetration and toxicity. *Skin Pharmacology & Physiology*. 32(1):32-42, 2018 Oct.

Zanker J, Scott D, Reijnierse E, Brennan-Olsen S, Daly R, Girgis C, Grossmann M, Hayes A, Henwood T, Hirani V, Inderjeeth C, Iuliano S, Keogh J, Lewis J, Maier A, Pasco J, Phu S, Sanders K, Sim M, Visvanathan R, Waters D, Yu S, Duque G. Establishing an operational definition of sarcopenia in Australia and New Zealand: delphi method based consensus statement. *Journal of Nutrition, Health and Aging*. Pp1-6, 2018 Oct.

Khan M, Roberts M. Challenges and innovations of drug delivery in older age. *Advanced Drug Delivery Reviews*. 135:3-38, 2018 Oct.

Khow K, Dollard J, Bray K, Smyth C, Chehade M, Theou O, Visvanathan R. A randomized controlled feasibility study to evaluate the effects of a goal-setting coaching intervention using feedback from an accelerometer on sedentary time in older people at risk of falls SMART-MOVE): a study protocol. *Pilot & Feasibility Studies*. 4:173, 2018.

Kim T, Peeters M, Thomas A, Gibbs P, Hool K, Zhang J, Ang A, Bach B, Price T. Impact of emergent circulating tumor DNA Ras mutation in panitumumab-treated chemoresistant metastatic colorectal cancer. *Clinical Cancer Research*. 24(22):5602-5609, 2018 Nov.

Paramasivan S, Lester S, Lau A, Ou J, Psaltis A, Wormald P-J, Vreugde S. Tertiary lymphoid organs: A novel target in patients with chronic rhinosinusitis. *Journal of Allergy and Clinical Immunology*. 142(5):1673-1676, 2018 Nov.

Prasanna T, Karapetis C, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorch M, Gibbs P, Yip D. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. *Acta Oncologica*. 57(11):1438-1444, 2018 Nov.

Shapiro J, Thavaneswaran S, Underhill C, Robledo K, Karapetis C, Day F, Nott L, Jefford M, Chantrill L, Pavlakakis N, Tebbutt N, Price T, Khasraw M, Van Hazel G, Waring P, Tejpar S, Simes J, GebSKI V, Desai J, Segelov E. Cetuximab alone or with Irinotecan for resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: The AGITG Randomized Phase II ICECREAM Study. *Clinical Colorectal Cancer*. 17(4):313-319, 2018 Dec.

Tapia Rico G, Karapetis C, Townsend A, Piantadosi C, Padbury R, Roy A, Maddern G, Moore J, Carruthers S, Roder D, Price T. Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. *Acta Oncologica*. 57(11):1455-1457, 2018 Nov.

PUBLICATIONS CONTINUED

If you wish to have a recent publication included, please send details to the BHI Communications Officer
rebecca.anderson@adelaide.edu.au

Chiew A, Wright D, Dobos N, McArdle K, Mostafa A, Newth A, Roberts M, Isbister G. 'Massive' metformin overdose. *British Journal of Clinical Pharmacology*. 84(12):2923-2927, 2018 Dec.

Chiew A, Wright D, Roberts M, Isbister G. Response to 'Comment on "Massive" metformin overdose' by Chiew *et al.* *British Journal of Clinical Pharmacology*. 84(12):2940-2941, 2018 Dec.

Davis S, Babidge W, McCulloch G, Maddern G. Fatal flaws in clinical decision making. *ANZ Journal of Surgery*. 2018 Nov doi: 10.1111/ans.14955.

Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K. Tofacitinib, an oral janus kinase inhibitor: Pooled efficacy and safety analyses in an Australian rheumatoid arthritis population. *Rheumatology & Therapy*. 5(2):383-401, 2018 Dec.

Kopsaftis Z, Sulaiman N, Mountain O, Carson-Chahhoud K, Phillips P, Smith B. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: Systematic review. *Systematic Reviews*. 7(1) Article Number: 213, 2018 Nov

Mehta P, Beltrame J. Myocardial infarction with non-obstructive coronary arteries: a humbling diagnosis in 2018. *Heart*. 0:1-2, 2018 Nov doi:10.1136/heartjnl-2018-314012.

Murray J, Barker A, Doeltgen S. Just add water: Can water protocols improve dysphagia management outcomes? *Journal of Speech-Language Pathology*. 20(3):129-13, 2018.

Roscioli E, Hamon R, Lester S, Jersmann H, Reynolds P, Hodge S. Airway epithelial cells exposed to wildfire smoke extract exhibit dysregulated autophagy and barrier dysfunction consistent with COPD. *Respiratory Research*. 19(1) Article Number: 234, 2018 Nov.

Smith H, Kenny B. Ethical conversations: Recipes for successful provision of nutrition and hydration at the end of life. *Journal of Speech-Language Pathology*. 20(3):169-173, 2018.

Wang H, Yang H, Xu Z, Liu X, Roberts M, Liang X. Anionic long-circulating quantum dots for long-term intravital vascular imaging. *Pharmaceutics*. 10(4) Article Number: 244, 2018 Dec.



THRF staff enjoyed participating in the Christmas Pageant!

Christmas Cheer!

On behalf of the entire THRF team, we would like to wish you and your families a very Merry Christmas and a wonderful New Year!

It's been another successful year and we are continually grateful to support some of the most innovative and world-class research taking place at the BHI. You should feel proud knowing the work you are undertaking will benefit our community and save lives.

We look forward to continuing to support promising research into the prevention of disease and improving patient care throughout South Australia.

In the Media 2018

As you may know, THRF's Communications team coordinates radio opportunities throughout the year that you are all welcome to take part of. With monthly community radio segments on Coast FM and weekend segments on Adelaide's FIVEaa, there are always opportunities for researchers to share their work with the public.

Dr Bill Panagopoulos enjoyed his radio experience with FIVEaa radio presenter Rilka Warbanoff.



This year, the following researchers from the BHI participated in THRF's radio segments:

Coast FM

- o Clementine Labrosciano, Translational Vascular Function Research Collaborative
- o Dr Kevin Fenix, Surgical Sciences Research Group & Liver Metastasis Research Group
- o Associate Professor Wendy Ingman, Breast Biology and Cancer Unit
- o Dr Danushka Wijesundara, Virology Group

5AA

- o Dr Katharina Richter, ENT Surgery
- o Dr Bill Panagopoulos, Breast Cancer Research Unit
- o Dr Irene Zinonos, Breast Cancer Research Unit

If you're eager to share your story with the wider media or have any questions please contact Antonia from the Communications team, acosta@hospitalresearch.com.au. We would love to hear from you!

Basil Hetzel Society Luncheon



A group of our loyal donors with Irene from THRF's Donor Engagement Group (second from the left, standing).

On Thursday 1 November 2018, more than 130 dedicated and highly valued supporters of THRF attended our Basil Hetzel Society Thank You Luncheon at the Glenelg Golf Club.

Attendees were treated to a very interesting and informative discussion from our four guest speakers who reflected how incredibly far medical research has come in treating diabetes, pancreatitis and kidney disease. The guest speakers were Professor Toby Coates – Director of Kidney and Pancreatic Islet Transplantation at the Royal Adelaide Hospital; Mr Christopher Drogemuller – Principal Medical Scientist; patient Margaret Harrigan who was the first person in South Australia to receive an islet transplant; and her husband Kerry.

The Luncheon is a wonderful opportunity for us to showcase the incredible impact our donors are making towards the South Australian community.